Overall, our findings indicate that ERK3 expression correlates with a more aggressive breast cancer phenotype, as evidenced by increased expression in metastatic samples, higher tumour grade, and poorer survival outcomes in breast cancer patients, regardless of subtype, although more commonly associated with TNBC. Here, MAPK12 is linked to neoplasm.